Orbimed Advisors LLC Gracell Biotechnologies Inc. Transaction History

Orbimed Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.83 - $4.9 $778,250 - $1.35 Million	275,000 Added 3.04%	9,308,726 $26.8 Million
Q2 2023 Aug 14, 2023	SELL	$1.45 - $6.07 $672,869 - $2.82 Million	-464,048 Reduced 4.89%	9,033,726 $34.4 Million
Q1 2023 May 15, 2023	BUY	$1.8 - $2.5 $2.9 Million - $4.03 Million	1,612,904 Added 20.46%	9,497,774 $17.7 Million
Q1 2021 May 17, 2021	BUY	$14.7 - $30.57 $116 Million - $241 Million	7,884,870 New	7,884,870 $121 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.